OncoMed Initiates Phase 1b Immuno-Oncology Combination Clinical Trial for …

OncoMed Initiates Phase 1b Immuno-Oncology Combination Clinical Trial for …

REDWOOD CITY, Calif., March 17, 2016 (GLOBE NEWSWIRE) — OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage company developing novel anticancer stem cell and immuno-oncology therapeutics, today announced dosing of the first …

(Visited 2 times, 1 visits today)
5
Like
Save

Comments

Comments are disabled for this post.